Myriad Genetics, Inc.
NASDAQMyriad Genetics heads into the post-earnings stretch with the stock trading close to multi-year lows, still loss-making at the operating level, and the Street in a cautious but not dismissive mood — a setup defined less by conviction in either direction than by a slow-motion search for a turning point. The company reported Q1 FY2026 results on May 5. Revenue came in at $200.4…
Snapshot as of 6 May 2026
Myriad Genetics heads into the post-earnings stretch with the stock trading close to multi-year lows, still loss-making at the operating level, and the Street in a cautious but not dismissive mood — a setup defined…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MYGN — free to start on ORTEX.
Sign up for free →Open MYGN on ORTEX